|
Home
Team Members
Patient Information
Clinical Trials
Basic Research
Fellowship
Program
Images
of Omaha
Contact Us:
Division of Allergy and Immunology
CreightonUniversity
601 North 30th Street, Suite 3M-100
Omaha,NE 68131
Ph.402.280.5975
Fx.402.280.5961
Email
|

The Center is
conducting the following new and exciting studies.
If you or someone
you know is eligible and interested,
we would love to hear
from you.
Please call (402)
280-5975.
Patient Demographics
The Omaha
area has a population of over 750,000. The Division’s clinical research
patient database alone is currently comprised of over 5,000 patients and is
constantly growing through the various recruitment efforts including media
advertising, health fair involvement as well as volunteer work. Our diverse
patient population is drawn not only from the Omaha
metropolitan area (urban/suburban), but also from the surrounding communities
in Eastern Nebraska and Western Iowa
(rural).
Areas
of Research
Acute and chronic otitis media
Acute and chronic urticaria
Acute sinusitis
Allergic asthma
Allergic bronchopulmonary aspergillosis
Allergic conjunctivitis
Angioedema
Asthma in pregnancy
B cell immunodeficiencies
Bronchitis
Common variable immunodeficiency
Contact dermatitis
Drug allergy
Exercise induced asthma
Food allergy and food hypersensitivity
Immunizations and immunoprophylaxis
Insect allergy
Latex allergy
Management of immunotherapy
Non-allergic asthma
Nasal polyposis
Perennial allergic rhinitis
Seasonal allergic rhinitis
Status asthmaticus
T-cell immunodeficiencies
Vasomotor rhinitis
Urticaria
The Division of Allergy and Immunology has a three bed inpatient unit suitable
for Phase I and Phase II studies. The Division conducts first-in-man
studies and has several model systems for proof of concept trials for
allergic and respiratory diseases. In addition, the basic research
laboratories of the Division are capable of assisting in clinical trials with
the measurement of biomarkers and mechanistic assays.
Procedures
and Equipment Available
Acoustic Rhinometry
Aeroallergen challenge
Exercise challenge
Hypertonic Saline challenge
Methacholine challenge
Bronchoprovocation Challenges
Biomarker Assays (Interleukins/Cytokines, Leukotrienes,
Histamine, Tryptase,
ECP)
Digital Electrocardiography Machine
Full Pulmonary Function Laboratory
Immediate and Delayed Hypersensitivity Skin Testing
Immunotherapy
Inpatient Beds
Nasal Allergen Challenges and Lavage
Nitric Oxide Measurements (oral/nasal)
Oral Desensitization
Parenteral Therapy Facilities
Phlebotomy
Pollen Collection
Radiology Suite for Routine X-Rays, MRIs ,CTs,
Nuclear Studies
Remote Data Entry Capabilities
Spirometry
Sputum Induction
Treadmill Exercise Testing
Investigators
Thomas B. Casale, M.D.
Professor of
Medicine and Medical Microbiology & Immunology; Chief, Division
of Allergy & Immunology Bio
Robert G. Townley, M.D.
Professor of
Medicine and Medical Microbiology & Immunology Bio
Againdra K.
Bewtra, M.B.B.S.
Associate
Professor of Medicine & Biomedical SciencesBio
Jeffrey R.
Stokes, M.D.
Associate
Professor of Medicine, Fellowship Program Director, Fellowship Program Bio
Russell J. Hopp,
D.O.
Professor of Pediatrics and Medicine;
Chief, Division of Pediatric Allergy & Clinical ImmunologyBio
Staff
Patrick De Nier: Operations
Manager
Tony Tony Romero,
MS: Budget,
Contracts, & Regulatory Documents
Dian Jean
Kessler, RN, BSN, CCRC:
Research Coordinator
Lori
Lori Mahon, RN, BSN,CCRC:
Research Coordinator
Jani Janie
Misfieldt, MA, CCRC:
Research Coordinator
Jean Danial
Avant, LPN, MA: Research
Coordinator
Current Clinical Trials
- Randomized,
double-blind, placebo-controlled, dose-response, cross-over study to
evaluate the effect of nasal carbon dioxide on nasal congestion via
acoustic rhinometry in subject with perennial allergic rhinitis.
- A Randomized,
Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the
Efficacy and Safety of Nasal Carbon Dioxide in the Treatment of Seasonal
Allergic Rhinitis.
- Phase 1B
randomized, placebo-controlled clinical trial to study the safety and
bronchodilatory effect of MK-0467 in patients with chronic asthma.
- Phase 2a,
randomized, double-blind, double-dummy, placebo and active controlled,
5-way crossover study to assess the bronchodilatory action, safety,
toleration and pharmacokinetics of single oral doses of PF-04191834 in
asthmatic patients.
- Phase 1B
Placebo-Controlled, Four-way Crossover Study to Determine the Effects of
an H3 Receptor Antagonist -PF-03654756 on Congestion Following a
Nasal Allergen Challenge in Subjects with Seasonal Allergic Rhinitis.
- A multicenter,
randomized study starting with a 4-week, 2-way crossover double-blind
treatment phase comparing the efficacy and safety of Combivent® CFC MDI
to albuterol HFA MDI followed by a 4-week open label Combivent Respimat®
treatment phase.
- Randomized,
double-blind, placebo-controlled, multi-center, phase III study of the
efficacy and safety of 300 IR sublingual immunotherapy (SLIT)
administered as allergen-based tablets once daily to adult patients
suffering from grass pollen rhinoconjunctivitis.
- Phase IIa
randomized double-blind placebo-controlled dose-escalating study to
evaluate the safety and effect on exercise challenge testing of multiple
fixed subcutaneous doses of MEDI-528, a humanized anti-interleukin-9
monoclonal antibody in adults with stable asthma and exercise-induced
bronchoconstriction
- A Randomized,
Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year
Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate
Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older
withPerennial Allergic Rhinitis
- Efficacy and
Safety Study to Compare CFC MDI to Albuterol HFA followed by Combivent
Repimat Treatment in Moderate to Severe Asthmatics, 19 years and older.
- Effects of
Rosiglitazone on Airway Hyperreactivity in Asthmatics, Age 19 and older
- Exhaled
Breath Condensate and Nitric Oxide:
Non-Invasive Evaluation of Lung Disease after Treatment with
Xolair in subjects with Allergic Asthma, 12 years and older.
|